Comparative Pharmacology
Head-to-head clinical analysis: STROMECTOL versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STROMECTOL versus VANSIL.
STROMECTOL vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category C
Category C
Anthelmintic
Anthelmintic